3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
2
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypertension
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Coronavirus Infections
1
COVID-19
1
Breast Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
Gemcitabine
34
pembrolizumab
27
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
Losartan
×
Clear all
NCT04447235
2022-08-09
TITAN
Instituto do Cancer do Estado de São Paulo
Phase 2
Terminated
77 enrolled